Home › Biotechnology › Racura Oncology (ASX:RAC)

Racura moves RC220 leukaemia trial towards first patient

Biotechnology By Ada Torres 4 min read

Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.

  • Sheba Medical Center ethics approval for the EMILI Phase 2b/3 AML trial
  • Phase 2b to enrol up to 68 patients and is funded from existing cash
  • Site activation is targeted by the end of 2026, with first patient treatment expected in Q1 2027
  • Phase 3 progression depends on results, funding and regulatory consultation
  • Trial will assess whether RC220 suppresses MYC activity in patient leukaemia cells

Sheba Approval Clears a Major Trial Hurdle

Racura Oncology Ltd (ASX:RAC) has secured site ethics approval from Israel’s Sheba Medical Center for the pivotal EMILI Phase 2b/3 trial of RC220 in adults with relapsed or refractory acute myeloid leukaemia. The decision allows the hospital to move towards site activation and enrolment, although minor updates to patient consent documents and final institutional governance approval remain outstanding.

Racura’s board has authorised the trial’s launch, with the initial Phase 2b stage covering up to 68 patients and funded from existing cash. Governance approval and trial initiation at Sheba are expected by the end of 2026, while the first patient is targeted to be enrolled and treated in the first quarter of 2027. Additional sites in Europe, the United States and Australia are planned for 2027, subject to regulatory approvals and feasibility.

Dose Optimisation Comes Before Phase 3

EMILI will begin with a six-patient lead-in at 175 mg/m², followed by randomised dose comparisons involving up to 62 further patients. Depending on the lead-in response rate, the trial will compare either 175 mg/m² against 200 mg/m², or 200 mg/m² against 250 mg/m². Interim assessments after 11, 16 and 21 patients per arm could allow the Phase 2b stage to finish early if the optimal dose becomes clear.

Image © Racura Oncology Ltd. From “Sheba Grants Ethics Approval for EMILI AML Trial”, 18 Nov 2026.

The design is intended to meet the US Food and Drug Administration’s Project Optimus approach, which emphasises selecting a dose based on the balance between benefit and side effects rather than simply choosing the highest tolerable dose. The Phase 2b endpoints include complete remission, complete remission with incomplete blood count recovery, safety, tolerability, pharmacokinetics, biomarker activity and the proportion of patients becoming eligible for an allogeneic stem-cell transplant.

The trial’s scientific rationale is tied to MYC, a gene frequently dysregulated in cancer. Racura says RC220, its formulation of (E,E)-bisantrene, is designed to reduce MYC expression by binding to G-quadruplex structures in the control region of the gene. The company’s MYC gene breakthrough had previously been presented alongside progress across three clinical programs, but EMILI will provide the first planned opportunity to test the mechanism in AML patients while measuring changes in leukaemia cells from blood samples.

Early Signals Remain Preliminary

Sheba has previously studied an earlier formulation of bisantrene in two small, single-centre, non-randomised Phase 2 studies. Each reported a 40% response rate: four of 10 patients responded in one monotherapy study, while six of 15 evaluable patients responded in a combination study. Those results informed EMILI’s design, but Racura explicitly says they do not predict the outcome of the new trial.

If Phase 2b identifies a recommended Phase 3 dose, the study is intended to transition seamlessly into a randomised Phase 3 comparison against standard-of-care therapy. That transition is conditional on the clinical data, funding and consultation with regulators at an End-of-Phase 2 meeting. The eventual Phase 3 sample size, comparator and statistical design have not yet been finalised.

The near-term milestones are therefore operational as much as clinical: completing Sheba’s governance review, conducting the site initiation visit, appointing a contract research organisation and securing FDA and European regulatory clearances. The more consequential readout may come later, when data from roughly 12 to 18 patients is expected to provide a more robust indication of whether RC220 is suppressing MYC activity in humans.

Bottom Line?

The approval moves EMILI from planning towards execution, but the investment case now turns on recruitment, dose selection and whether the MYC mechanism can be demonstrated alongside meaningful AML responses.

Questions in the middle?

  • Can Racura complete Sheba governance approval and treat the first patient by Q1 2027?
  • Will interim Phase 2b analyses identify a dose early enough to accelerate the Phase 3 transition?
  • Will MYC suppression in patient samples correlate with remission and transplant eligibility?

Sources